Korro Bio, Inc./$KRRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Korro Bio, Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Ticker
$KRRO
Sector
Primary listing
Employees
92
Headquarters
Website
Korro Bio, Inc. Metrics
BasicAdvanced
$376M
-
-$9.76
-
-
Price and volume
Market cap
$376M
52-week high
$55.89
52-week low
$10.29
Average daily volume
252K
Financial strength
Current ratio
5.976
Quick ratio
5.675
Long term debt to equity
36.669
Total debt to equity
38.776
Profitability
EBITDA (TTM)
-93.984
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,454.47%
Operating margin (TTM)
-1,569.08%
Effective tax rate (TTM)
-0.10%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-28.65%
Return on equity (TTM)
-58.34%
Valuation
Price to revenue (TTM)
59.742
Price to book
3.27
Price to tangible book (TTM)
3.27
Price to free cash flow (TTM)
-5.081
Free cash flow yield (TTM)
-19.68%
Free cash flow per share (TTM)
-7.889
Growth
Earnings per share change (TTM)
-35.44%
Bulls say / Bears say
Korro’s lead program KRRO-110 received orphan drug designation from the European Medicines Agency on July 21, 2025, providing protocol assistance, reduced fees, and market exclusivity incentives for its AATD treatment (Nasdaq).
As of August 12, 2025, over 80% of planned healthy volunteer cohorts in the Phase 1/2a REWRITE study of KRRO-110 were dosed with no treatment-emergent serious adverse events or dose-limiting toxicities, demonstrating a favorable safety profile (Nasdaq).
Korro ended Q1 2025 with $139.0 million in cash, cash equivalents, and marketable securities, securing a financial runway into 2027 to support its RNA editing pipeline (Nasdaq).
In Q1 2025, Korro reduced its workforce by approximately 20% to streamline operations, a move that could undermine program execution and employee morale during critical development phases (Nasdaq).
Korro reported a net loss of $23.4 million for Q1 2025, up from $19.6 million in Q1 2024, indicating rising research and operational expenses without offsetting revenues (Nasdaq).
By June 30, 2025, cash, cash equivalents, and marketable securities declined to $119.6 million—down from $163.1 million at year-end 2024—potentially pressuring funding for upcoming trials and portfolio expansion (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 23 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Korro Bio, Inc. stock?
Korro Bio, Inc. (KRRO) has a market cap of $376M as of October 29, 2025.
What is the P/E ratio for Korro Bio, Inc. stock?
The price to earnings (P/E) ratio for Korro Bio, Inc. (KRRO) stock is 0 as of October 29, 2025.
Does Korro Bio, Inc. stock pay dividends?
No, Korro Bio, Inc. (KRRO) stock does not pay dividends to its shareholders as of October 29, 2025.
When is the next Korro Bio, Inc. dividend payment date?
Korro Bio, Inc. (KRRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Korro Bio, Inc.?
Korro Bio, Inc. (KRRO) does not currently have a Beta indicator.